Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Core Viewpoint - Shuttle Pharmaceuticals is making significant progress in its Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with 63% enrollment achieved and 72% of enrolled patients completing all treatment cycles, indicating a well-tolerated therapy [1][6]. Recent Activities - The Phase 2 clinical trial is being conducted in collaboration with leading cancer centers across the U.S. and aims to complete enrollment later this year, with data readouts expected in 2026 [1][3]. - Ropidoxuridine is designed as a radiation sensitizer to improve treatment outcomes for glioblastoma patients, a type of brain cancer with no known cure [1][7]. Clinical Trial Design - The trial involves randomizing 40 patients into two dose levels: 20 patients receiving 1,200 mg/day and 20 patients receiving 960 mg/day, to identify the optimal dose for glioblastoma treatment in combination with radiation therapy [2]. Market Opportunity - Approximately 800,000 patients in the U.S. receive radiation therapy for cancer annually, with 50% treated for curative purposes. The market for radiation sensitizers targets the 400,000 patients treated curatively, expected to grow by over 22% in the next five years [4]. Financial Update - The company ended the quarter with $4.8 million in cash after a private placement that raised $4.25 million in June 2025 [6]. - A reverse stock split was completed in June 2025 as part of a strategic initiative for Nasdaq compliance [6]. Leadership Changes - George Scorsis was appointed as the Chairman of the Board, and Christopher Cooper, the current Interim CEO, was appointed to the Board, both bringing extensive experience in management and finance [6].